Published in Pharma Law Weekly, September 26th, 2006
The new Pharmacor report Osteoporosis finds that although several emerging drugs will capture significant patient and market share, the entry of generic alendronate will be a major factor in causing the market to plateau at $7.5 billion in 2015, up from $6.3 billion in 2005. The report also finds that bisphosphonates, including alendronate, will continue to dominate the market to treat osteoporosis in the United States, Japan, France, Germany, Italy, Spain,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.